Mouse anti-GLP-1R monoclonal antibody was from DSHB (Iowa, IA, USA)
GLP-1RAs have shown promising results in treating non-alcoholic fatty liver disease (NAFLD) in patients with T2DM [51]
How does genetic variation in GLP-1 receptors affect missed-dose recovery
Patent landscape: Core semaglutide patent expired in India (March 2026) However, oral formulation patent remains valid till 2031 Leading to ongoing legal disputes in the market Clinical validation: Dr Reddys conducted a head-to-head study in India, showing the drug to be non-inferior to the innovator product supporting its approval
Group on behalf of the I 201 S, Beck DE, Sweeney WB, McCarter MD
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (Lead-6)